Redmile Group, LLC Fate Therapeutics Inc Put Options Transaction History
Redmile Group, LLC
- $1.28 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Vanguard Group Inc Valley Forge, PA10.3MShares$16 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$15.7 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$7.5 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.79 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$5.51 Million0.15% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $150M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...